Franklin FTSE South Korea ETF vs Nuwellis Inc — how do they compare? Franklin FTSE South Korea ETF trades at $58.5 (market cap $1.83B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Franklin FTSE South Korea ETF is far larger — about 831.8× Nuwellis Inc's market cap, and Franklin FTSE South Korea ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Franklin FTSE South Korea ETF for 15 Days and Nuwellis Inc for 26 Days on average.
| FLKR | NUWE | |
|---|---|---|
Market Cap | $1.83B | $2.20M |
Volume | 679,902 | 121,544 |
Sector | Broad Market / Factor | Health |
52-Week High | $72.25 | $146.65 |
52-Week Low | $27.09 | $0.68 |
Typical Hold Time | 15 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.
Read more on FLKR →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →